1- Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the
Medical Outcomes Study. JAMA 1989.262:914-919.
2- Murray CJL, Lopez AD, eds. Summary: The Global Burden of Disease: A Comprehensive Assessment of
Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, Mass:
Harvard School of Public Health on behalf of the World Health Organization and the World Bank, Harvard
University Press; 1996.
3- Lebwobitz BD, Pearson JL, Schneider LS, et al. Diagnosis and treatment of depression in late life: consensus
statement update. JAMA 1997; 278:1186-1190.
4- Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and non response to antidepressant therapy:
current approaches and treatment option. J Clin Psychiatry 2002; 63: 826 – 837.
5- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.
Washington, DC: American Psychiatric Association; 1994.
6- Hamilton M.A rating scale for depression. J Neurol Neurosurg psychiatry 1960; 23:56-62.
7- Olver JS, Burrows GD, Norman TR. Third – generation antidepressants: do they offer advantages over the
SSRIS? CNS Drugs 2001; 15:941-954.
8- Goldstein BJ; Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders, 3:
tolerability, safety and pharmacoeconomics. J Psyschopharmacol 1998; 12 (3 suppl B): S55 – 87.
9- Burke WJ, Gergel I, Bose A. Fixed – dose trial of the single isomer SSRI escitalopram in depressed outpatients. J
Clin psychiatry 2002; 63: 331-336.
10- Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen
Psychiatry 2000; 57:503-509.
11- Barbey JT. Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998; 59 (suppl 15): 42 – 48.
12- Thase ME: Long – term nature of depression. J Clin Psychitry 1999; 60(suppl 14):3-9.
13- Donoghue J. Antidepressant use patterns in clinical: compare sons among tricyclic antidepressants and selective
serotonin reuptake inhibitors. Acta Psychiatr Scand suppl 2000; 403:57-61.
14 - Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy:
current approaches and treatment option. J Clin Psychiatry 2002; 63 826 – 837.
15- Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effect-tive and well tolerated in a placebocontrolled
study in depression in primary care. Int Clin psychopharmacol 2003; 18:211-217.
16- Thase ME, for the Venlafaxine XR 209 Study Group. Efficacy and toler ability of once – daily venlafaxine
extended release (XR) in outpatients with major depression. J Clin Psychiatry 1997; 58:393-398.
17- Wade AG, Michael Lemming O,Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a
placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17:95-102.
18- Owens MJ, Knight DL, Nemeroff CB. Second – generation SSRIS: human monoamine transporter binding
profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50:345 –350.
19- Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective
serotonin reuptake inhibitors. Acta Psychiatr Scand suppl 2000; 403:17-25.
20- Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venla - faxine and SSRIS: a pooled analysis
of patients with depression. Biol Psychiatry 2002; 52: 1166-1174.
21- Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonim
reuptake inhibitors. Bull, Br J Psychiatry 2001; 178:234-241.
22- Dunner DL, Goldstein DJ, Mallinckrodt C,et al. Duloxetine in treatment of anxiety symptoms associated with
depression. Depress Anxiety 2003; 18:53-61.
23- Guy W.ECDEU Assessment Manual for psychopharmacology. US Dept Health, Education, and Welfare
publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976. 218-222.
24- Montgomery SA, Huusom AKT, Bothmer J.A radomised study comparing escitalopram with venlafaxine XR in
primary care patients with major depressive disorder. Neuro psychobiology 2004; 50:57-64.